UY36771A - Moduladores cot y métodos de uso de los mismos - Google Patents

Moduladores cot y métodos de uso de los mismos

Info

Publication number
UY36771A
UY36771A UY0001036771A UY36771A UY36771A UY 36771 A UY36771 A UY 36771A UY 0001036771 A UY0001036771 A UY 0001036771A UY 36771 A UY36771 A UY 36771A UY 36771 A UY36771 A UY 36771A
Authority
UY
Uruguay
Prior art keywords
methods
same
cot
modulators
cot modulators
Prior art date
Application number
UY0001036771A
Other languages
English (en)
Inventor
William J Watkins
Elizabeth M Bacon
Balan Gayatri
Christopher T Clark
Kim Musong
Scott D Schroeder
Neil H Squires
Kirk L Stevens
Nathan E Wright
Sheila M Zipfel
John O Link
Thorsten A Kirschberg
Chien-Hung Chou
Jeromy J Cottell
Phillips Gary
James G Taylor
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY36771A publication Critical patent/UY36771A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La presente divulgación se refiere en general a moduladores de Cot (cáncer de tiroides Osaka) y métodos de uso y producción de los mismos.
UY0001036771A 2015-07-06 2016-07-06 Moduladores cot y métodos de uso de los mismos UY36771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
UY36771A true UY36771A (es) 2017-01-31

Family

ID=56411943

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036771A UY36771A (es) 2015-07-06 2016-07-06 Moduladores cot y métodos de uso de los mismos

Country Status (40)

Country Link
US (6) US20170008905A1 (es)
EP (3) EP3896064A1 (es)
JP (5) JP6430060B2 (es)
KR (5) KR102073641B1 (es)
CN (3) CN109879859B (es)
AU (4) AU2016290820B2 (es)
BR (1) BR102016015656B1 (es)
CA (1) CA2971640C (es)
CL (1) CL2017003356A1 (es)
CO (1) CO2017013351A2 (es)
CR (1) CR20170599A (es)
CU (1) CU20170172A7 (es)
CY (1) CY1121750T1 (es)
DK (1) DK3191470T3 (es)
DO (1) DOP2017000311A (es)
EA (1) EA036788B1 (es)
EC (1) ECSP17084635A (es)
ES (2) ES2872076T3 (es)
HR (1) HRP20190853T1 (es)
HU (1) HUE043310T2 (es)
IL (4) IL274568B (es)
LT (1) LT3191470T (es)
MA (1) MA39422B1 (es)
ME (1) ME03425B (es)
MX (1) MX370984B (es)
MY (1) MY196173A (es)
NZ (2) NZ750707A (es)
PE (1) PE20180462A1 (es)
PH (2) PH12018500031A1 (es)
PL (2) PL3191470T3 (es)
PT (2) PT3456717T (es)
RS (1) RS58639B1 (es)
SA (1) SA517381350B1 (es)
SG (1) SG11201702041PA (es)
SI (2) SI3191470T1 (es)
SV (1) SV2017005605A (es)
TW (3) TWI634112B (es)
UA (1) UA123010C2 (es)
UY (1) UY36771A (es)
WO (1) WO2017007689A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EP3319955B1 (en) 2015-07-06 2020-11-25 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitrils as cot modulators
EP3896064A1 (en) 2015-07-06 2021-10-20 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivatives as cancer osaka thyroid (cot) modulators for treating crohn's disease and ulcerative colitis
WO2018005435A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
HUE063811T2 (hu) * 2016-08-19 2024-02-28 Gilead Sciences Inc HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JPWO2019065516A1 (ja) * 2017-09-26 2020-09-10 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI770527B (zh) * 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN114585619A (zh) 2019-08-29 2022-06-03 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
CA3175541A1 (en) * 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
AU2021245924B2 (en) 2020-04-02 2024-02-29 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
EP4172157A1 (en) 2020-06-25 2023-05-03 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TW202300146A (zh) 2021-03-03 2023-01-01 瑞士商愛杜西亞製藥有限公司 經三唑基-甲基取代的α-D-吡喃半乳糖苷衍生物
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
KR20240019340A (ko) * 2021-06-11 2024-02-14 뉴로내슨트, 아이엔씨. 헤테로시클릭 유형의 친유성 소분자 치료의 지질 제제를 위한 방법 및 조성물
TW202337439A (zh) 2021-12-03 2023-10-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
NL7800191A (nl) 1977-01-10 1978-07-12 Ciba Geigy Anthelmintisch preparaat.
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ503079A (en) 1997-08-28 2002-07-26 Nissan Chemical Ind Ltd Cyanoacrylate-containing antibacterial and antifungal agents, algicides and antifouling agents
DK1097158T3 (da) 1998-07-10 2006-05-29 Massachusetts Inst Technology Ligander til metaller og metalkatalyserede metoder
CN1144786C (zh) * 1998-09-29 2004-04-07 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
GEP20074230B (en) 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
WO2004078176A1 (en) 2003-03-03 2004-09-16 F. Hoffmann-La Roche Ag 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators
KR20060066733A (ko) 2003-08-19 2006-06-16 와이어쓰 홀딩스 코포레이션 4-아미노-3-퀴놀린카보니트릴의 제조방법
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006124944A1 (en) 2005-05-18 2006-11-23 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
CA2608540A1 (en) 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
WO2007050732A1 (en) 2005-10-28 2007-05-03 Abbott Laboratories INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
WO2008055950A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CA2791247C (en) 2010-03-09 2019-05-14 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
RU2600928C2 (ru) * 2010-06-09 2016-10-27 Тяньцзинь Химэй Байо-Тек Ко., Лтд Цианохинолиновые производные
EP2708540B1 (en) 2011-05-10 2018-07-25 Kyowa Hakko Kirin Co., Ltd. Pyrimido-diazepinone compound
WO2013004652A1 (de) 2011-07-04 2013-01-10 Bayer Intellectual Property Gmbh Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013062027A1 (ja) 2011-10-27 2013-05-02 大正製薬株式会社 アゾール誘導体
CN104105485B (zh) 2011-11-11 2017-04-12 吉利德阿波罗公司 Acc抑制剂和其用途
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
WO2015089170A1 (en) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Bicyclic alkyl compounds and synthesis
JP6741343B2 (ja) 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
EP3166938A4 (en) * 2014-07-11 2018-01-17 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
CA2961605C (en) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
JP2017528471A (ja) 2014-09-24 2017-09-28 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
ES2842749T3 (es) 2014-12-23 2021-07-14 Gilead Sciences Inc Procesos para preparar inhibidores de ASK1
CN107106873A (zh) 2015-01-09 2017-08-29 吉利德阿波罗公司 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗
CA2974004A1 (en) 2015-01-16 2016-07-21 3M Innovative Properties Company Systems and methods for selecting grid actions to improve grid outcomes
EP3319955B1 (en) * 2015-07-06 2020-11-25 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitrils as cot modulators
EP3896064A1 (en) 2015-07-06 2021-10-20 Gilead Sciences, Inc. 4,6-diamino-quinoline-3-carbonitrile derivatives as cancer osaka thyroid (cot) modulators for treating crohn's disease and ulcerative colitis
CN106928198B (zh) 2015-12-31 2020-07-28 成都先导药物开发股份有限公司 磺酰胺衍生物及其制备方法与应用
CA3220447A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2017221944A1 (ja) 2016-06-21 2017-12-28 パナソニックヘルスケアホールディングス株式会社 カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法
WO2018005435A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CA3137479A1 (en) 2017-03-03 2018-09-07 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
CA3059883A1 (en) 2017-04-12 2018-10-18 Gilead Sciences, Inc. Methods of treating liver disease
TWI814744B (zh) 2017-10-06 2023-09-11 美商基利科學股份有限公司 包含acc抑制劑之組合療法
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
US20220143153A1 (en) 2019-03-08 2022-05-12 The Regents Of The University Of California Compositions and methods for treating acne
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
AU2021245924B2 (en) 2020-04-02 2024-02-29 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法

Also Published As

Publication number Publication date
CA2971640A1 (en) 2017-01-12
MA39422A (fr) 2017-07-19
SV2017005605A (es) 2018-07-18
HUE043310T2 (hu) 2019-08-28
ME03425B (me) 2020-01-20
RS58639B1 (sr) 2019-05-31
PH12018500031B1 (en) 2018-07-09
NZ738525A (en) 2019-03-29
KR20220129667A (ko) 2022-09-23
UA123010C2 (uk) 2021-02-03
TW202114673A (zh) 2021-04-16
PT3191470T (pt) 2019-06-05
IL293770A (en) 2022-08-01
IL293770B2 (en) 2023-07-01
AU2019203122B2 (en) 2020-10-01
CN107922390A (zh) 2018-04-17
ES2872076T3 (es) 2021-11-02
AU2020257055A1 (en) 2020-11-12
JP6430060B2 (ja) 2018-11-28
JP6781221B2 (ja) 2020-11-04
KR102443575B1 (ko) 2022-09-16
PH12020551397A1 (en) 2021-08-16
JP2018520161A (ja) 2018-07-26
CY1121750T1 (el) 2020-07-31
AU2022204050A1 (en) 2022-06-30
EA201792613A1 (ru) 2018-06-29
TWI748539B (zh) 2021-12-01
SI3191470T1 (sl) 2019-04-30
TWI634112B (zh) 2018-09-01
PH12018500031A1 (en) 2018-07-09
MX370984B (es) 2020-01-09
AU2022204050B2 (en) 2024-04-18
KR102073641B1 (ko) 2020-02-05
CN109879859B (zh) 2022-01-25
PT3456717T (pt) 2021-05-26
BR102016015656B1 (pt) 2021-11-03
HRP20190853T1 (hr) 2019-06-28
CR20170599A (es) 2018-02-28
CU20170172A7 (es) 2018-06-05
KR20200013120A (ko) 2020-02-05
JP2019178178A (ja) 2019-10-17
EP3191470B1 (en) 2019-02-27
JP2021042252A (ja) 2021-03-18
PL3456717T3 (pl) 2021-10-25
IL256433A (en) 2018-02-28
JP2018193405A (ja) 2018-12-06
IL293770B1 (en) 2023-03-01
EP3456717A1 (en) 2019-03-20
JP7138155B2 (ja) 2022-09-15
CO2017013351A2 (es) 2018-05-21
IL274568B (en) 2022-07-01
SI3456717T1 (sl) 2021-08-31
US11066414B2 (en) 2021-07-20
CA2971640C (en) 2020-09-22
US20170008905A1 (en) 2017-01-12
US11905299B2 (en) 2024-02-20
KR20190045416A (ko) 2019-05-02
TWI699361B (zh) 2020-07-21
MY196173A (en) 2023-03-17
AU2016290820A1 (en) 2018-01-18
US20180237455A1 (en) 2018-08-23
AU2020257055B2 (en) 2022-03-31
ECSP17084635A (es) 2018-01-31
CL2017003356A1 (es) 2018-07-06
JP6906021B2 (ja) 2021-07-21
IL266995B (en) 2020-05-31
SG11201702041PA (en) 2017-04-27
CN109879859A (zh) 2019-06-14
AU2016290820B2 (en) 2019-03-07
JP2022082816A (ja) 2022-06-02
DOP2017000311A (es) 2018-01-15
NZ750707A (en) 2023-09-29
EA036788B1 (ru) 2020-12-21
IL256433B (en) 2019-06-30
EP3456717B1 (en) 2021-03-17
US9878995B2 (en) 2018-01-30
EP3896064A1 (en) 2021-10-20
SA517381350B1 (ar) 2021-03-11
BR102016015656A2 (pt) 2020-09-24
KR101974793B1 (ko) 2019-05-02
PE20180462A1 (es) 2018-03-06
US20200123172A1 (en) 2020-04-23
US20170152240A1 (en) 2017-06-01
MA39422B1 (fr) 2019-03-29
TW201908305A (zh) 2019-03-01
ES2734713T3 (es) 2019-12-11
IL266995A (en) 2019-07-31
TW201712005A (zh) 2017-04-01
WO2017007689A1 (en) 2017-01-12
EP3191470A1 (en) 2017-07-19
US20190248807A1 (en) 2019-08-15
LT3191470T (lt) 2019-05-10
DK3191470T3 (en) 2019-04-15
IL274568A (en) 2020-06-30
CN107922390B (zh) 2019-05-10
KR20240008398A (ko) 2024-01-18
KR20180022982A (ko) 2018-03-06
AU2019203122A1 (en) 2019-05-30
CN114380799A (zh) 2022-04-22
PL3191470T3 (pl) 2019-08-30
US20230002407A1 (en) 2023-01-05
MX2017004737A (es) 2017-06-19

Similar Documents

Publication Publication Date Title
DOP2017000311A (es) Moduladores cot y métodos de uso de los mismos
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
DOP2023000172A (es) Moduladores de cot y métodos de uso de los mismos
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
UY35475A (es) 4-amino-6-(piridil y 2-fenilsustituido)-picolinatos y 6-amino-2-(piridil y 2-fenilsustituido)-pirimidin-4-carboxilatos novedosos y su uso como herbicidas
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
AR121189A2 (es) Anticuerpos anti-tigit y métodos de uso
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TWD188964S (zh) 嬰兒揹帶
NI201500033S (es) Chainsaw ms382-1119
TWD169258S (zh) 蹦床
AU351463S (en) Building and/or structure
AU351525S (en) Light fitting
AU351524S (en) Light fitting
AU349736S (en) Chair base

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221125